FDA Encourages Shift From Animal Testing Models
The FDA is urging pharmaceutical companies to reduce reliance on animal testing. Betts Lacroix stated that current technology does not yet support complete replacement of animal models.
fda.govThe FDA has directed companies to move away from animal models in drug development. The agency said the change aims to incorporate newer testing methods where possible. Betts Lacroix said the technology is not yet advanced enough to entirely abandon animal models. Lacroix added that some animal testing remains necessary for safety and efficacy data.
The FDA continues to accept data from both traditional and alternative testing methods. Companies may submit results from non-animal models when the data meet agency standards.
Drug developers are evaluating how to integrate new testing technologies while maintaining compliance. No specific timeline for full transition has been announced.
Key Facts
Potential Impact
- 01
Companies may increase investment in alternative testing technologies.
Transparency Panel
Related Stories
NprWHO Director Visits Congo as Ebola Outbreak Spreads
The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.
Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery
Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…